ReleaseWire Connect

The global cardiovascular surgery devices market is forecast to reach $1.6 billion by 2017, with a compound annual growth rate (CAGR) of -1.3% from 2010-2017. The cardiovascular surgery devices market is expected to decline in this period due to the increasing adoption of alternative treatment procedures, such as percutaneous coronary intervention (PCI) and other minimally invasive interventions, and the shortage of cardiac surgeons in the US. In addition to this, a falling average selling price (ASP) and cost containment pressures in developed economies will also negatively affect the cardiovascular surgery devices market.

The Quebec's Minister of Environment and Sustainable Development released a report by the Bureau d’Audiences Publiques sur l’Environnement (BAPE) in March 2011. This report proposed a Strategic Environmental Assessment (SEA) of the shale gas industry in the province of Quebec, which is expected to take up to two and half years to complete. The Quebec government has prohibited any shale drilling in the province until the study is completed. Consequently, the drilling in the Utica shale in Quebec has been stopped, except for the drilling required to collect the data required for the study. Additionally, a higher royalty regime proposed in 2011, if adopted, will result in lower profitability for operations by the oil and gas companies in Quebec. This will also affect future drilling activities negatively. Thus, the scenario of development for the Utica shale in Quebec is subject to the SEA report and government’s decision on the report’s findings.

This report gives you access to the category-level spending outlooks, budgets, supplier selection criteria, business challenges and investment opportunities of leading purchase decision makers. The report also identifies future growth of buyers and suppliers, M&A and e-procurement. This report not only grants access to the opinions and strategies of business decision makers and competitors, but also examines their actions surrounding business priorities. The report also provides access to information categorized by region, company type and sizes.

The Cardiovascular Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the cardiovascular partnering deals and agreements entered into by the worlds leading healthcare companies.

This profile is the essential source for top-level industry data and information relating to the global UGS industry. It provides asset level information relating to the active and planned gas storage sites across the globe. The profiles of the major companies operating in the UGS industry are also included in the report. The latest news and deals pertaining to the sector are also provided and analyzed.

MES is emerging as a superior product for flexible and integrated production. An MES combines all the properties required for modern production management in a comprehensive software system. This system is the basic and operational platform for all the enterprises evolving towards the digital factory of the future.

The global healthcare packaging market is a complex and large market. The varied factors affecting the drug demand and consumption as well the development of medical practices will determine the growth of this market in future. Also, being a vital industry, the healthcare packaging market is directly linked to economic development. As emerging economies grow, demand for healthcare packaging will increase, further strengthening the market. Visiongain calculates that the global healthcare packaging market will reach $93.9bn in 2012.

In 2010, the global urological disorders market was estimated to be worth $8.1 billion, representing a Compound Annual Growth Rate (CAGR) of 7.9% between 2002 and 2010. In the same year, Urinary Incontinence (UI) and Benign Prostatic Hyperplasia (BPH) combined accounted for 79% of the total urological disorders market with revenue of $6.5 billion. Solifenacin and tolterodine for UI and dutasteride and tamsulosin for BPH dominated the market in 2010 and generated $2 billion and $1.8 billion respectively.

“Healthcare, Regulatory and Reimbursement Landscape-Japan”. The report is an essential source of information and an analysis on the healthcare, regulatory and reimbursement landscape of Japan. The report identifies the key trends in the healthcare market of Japan. The report also provides insights on the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Japan. Most importantly, the report provides valuable insights on the trends and segmentation of pharmaceutical and medical devices market. This report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by GlobalData’s team of industry experts.

Our analysis suggests that the global aspergillosis therapeutics market was worth $1.6 billion in 2011, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 1.5% for the next eight years, to reach $1.9 billion by 2019. The aspergillosis therapeutics market is formed primarily by four classes of antifungal drugs: polyenes, triazoles, echinocandins and allylamines. The most prescribed drugs for the treatment of aspergillosis are Vfend, Noxafil, Cancidas, itraconazole and amphotericin B, of which the latter two are generics. Vfend is the first line of therapy and the gold standard of treatment for aspergillosis. The global aspergillosis therapeutics market is showing slow growth due to the expiry of the patents for the major marketed drugs. Cancidas’ patent will expire in 2015, followed by the expiry of the patents for Vfend and Noxafil in 2015 and 2019 respectively. However, market growth will be augmented by the increasing incidence rate and the expected launch of a new triazole, Isavuconazole. Isavuconazole’s launch will not have a significant impact on the aspergillosis therapeutics market as it is a me-too product, and faces competition with the generic triazole drugs.